Home › Compound Library › Fluoxetine (Prozac)

Fluoxetine (Prozac)

SSRIprescriptionoral · inferred

SSRI with the longest half-life in its class. Active metabolite norfluoxetine persists 7-15 days. Both parent and metabolite inhibit their own metabolism, increasing half-life with chronic use.

Projected serum levels — 20 mg, once daily

Fluoxetine (Prozac)
Fluoxetine (Prozac) modeled serum levels, 20 mg once daily over 16 days Population-based pharmacokinetic estimate. Steady state reached after approximately 7 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 12 Day 16 Time on a regular schedule ≈ steady state · day 7
Fluoxetine (Prozac) modeled serum levels with a loading dose of 60 mg, then 20 mg once daily The first dose is larger so levels approach steady state faster. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 12 Day 16 Time on a regular schedule

Maintenance schedule: 20 mg once daily (oral).

Loading schedule: 60 mg on day 1, then 20 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~7 days: peak ≈ 0.99 mg, trough ≈ 0.75 mg body load. Population-based estimate over 16 days for a 20 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
SSRI
Route modeled
Oral
Model confidence
inferred
Half-life
2 days
Common dose
20 mg
Suggested maximum
80 mg/day
Reference dose range
10–80 mg (single dose)
Suggested cadence
once daily
Validated against
40 mg oral — Cmax 0.015 mg/L at 6 h

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + Fluoxetine (Prozac) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and Fluoxetine (Prozac) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + Fluoxetine (Prozac) Serotonin risk

    25I-NBOMe and Fluoxetine (Prozac) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Fluoxetine (Prozac) Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Fluoxetine (Prozac) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Fluoxetine (Prozac) Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Fluoxetine (Prozac) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + Fluoxetine (Prozac) Serotonin risk

    4-AcO-DMT (Psilacetin) and Fluoxetine (Prozac) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-MMC (Mephedrone) + Fluoxetine (Prozac) CYP inhibition

    Fluoxetine (Prozac) reversible_inhibitor of CYP2D6 predicted to change 4-MMC (Mephedrone) AUC by ~2.27x

Serum checks 502 modeled interaction pairings for fluoxetine (prozac) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) March J et al. · JAMA, 2004 DOI

    Landmark NIMH-funded trial found combination of fluoxetine plus CBT was the most effective treatment for adolescent depression (71% response), superior to either alone.

  2. Efficacy of fluoxetine in bulimia nervosa: a double-blind, placebo-controlled, multicenter trial Fluoxetine Bulimia Nervosa Collaborative Study Group · New England Journal of Medicine, 1992 DOI

    Pivotal RCT establishing fluoxetine 60 mg/day as effective for bulimia nervosa, reducing binge-eating episodes by 67% and vomiting by 56% compared to placebo.

  3. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration Kirsch I et al. · PLoS Medicine, 2008 DOI

    Influential meta-analysis of FDA trials found antidepressants including fluoxetine showed clinically meaningful benefit primarily in severely depressed patients, sparking debate about SSRI efficacy.

3 published studies referenced in the app, each with a plain-language summary.